Mauna Kea Technologies announces results of its Combined General Meeting of June 6, 2024

All the resolutions proposed by the Board of Directors were adopted 

Paris and Boston, June 7, 2024 - 8:00 a.m. CEST - Mauna Kea Technologies (Euronext Growth: ALMKT), inventor of Cellvizio®, the multidisciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE) platform, held its Combined General Meeting of June 6, 2024, which was chaired by Mr. Sacha Loiseau, Chairman of the Board of Directors and CEO. 

With a quorum of 44.2%, all the resolutions proposed by the Board of Directors have been adopted, including the approval of the annual and consolidated financial statements for the year ended December 31, 2023, the renewal of directors’ mandates, as well as delegations granted to the Board of Directors related to financial transactions. The 26th resolution, relating to the delegation to be granted to the Board of Directors for the purpose of carrying out capital increases with cancellation of shareholders' preferential subscription rights in favor of subscribers of a company savings plan, which was submitted but not approved by the Board of Directors, has been rejected. 

Details on the vote results are available on the Company’s website.